Ulcerative Colitis

Disclaimer: This document provides comprehensive medical information for educational and informational purposes only and does not constitute medical advice. It is intended for healthcare professionals to supplement their knowledge and should not be used as a substitute for professional clinical judgment, diagnosis, or treatment. Medical practice is constantly evolving, and information may become outdated. Always refer to the most current clinical guidelines, expert consensus, and individual patient circumstances. Patient care decisions must be made by a qualified healthcare professional.

Overview

• Definition: Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease (IBD) characterized by continuous inflammation of the colonic mucosa, typically starting in the rectum and extending proximally to varying degrees. The inflammation is superficial, affecting the mucosa and submucosa, and manifests with crypt abscesses, architectural distortion, and depletion of goblet cells.
• Epidemiology:
  • Incidence: Varies geographically, but generally 9-12 cases per 100,000 person-years in Western countries. Higher in Northern Europe and North America.
  • Prevalence: 150-250 cases per 100,000 persons.
  • Age of Onset: Bimodal distribution, with the primary peak between 15-30 years and a smaller second peak between 50-70 years.
  • Gender: Affects males and females nearly equally, though some studies suggest a slight male predominance.
  • Ethnicity: More common in Caucasians, particularly those of Ashkenazi Jewish descent. Increasing incidence noted in developing countries.
• Classification: UC is classified based on the extent of disease, which dictates prognosis and treatment strategy. The Montreal Classification is commonly used:
  • E1: Ulcerative Proctitis: Inflammation limited to the rectum (proximal to the rectosigmoid junction, i.e., <15 cm from the anal verge).
  • E2: Left-sided Colitis: Inflammation extends beyond the rectum but not beyond the splenic flexure (i.e., from the rectum up to the splenic flexure).
  • E3: Extensive Colitis (Pancolitis): Inflammation extends proximal to the splenic flexure, potentially involving the entire colon.

Pathophysiology

• Mechanism: UC results from a complex interplay of genetic predisposition, environmental factors, and an aberrant immune response directed against commensal gut microbiota in a genetically susceptible host.
  • Immune Dysregulation: Involves a dysregulated mucosal immune system with an exaggerated inflammatory response. Key players include:
    • Innate Immunity: Defects in epithelial barrier function, altered antimicrobial peptide production, and dysregulation of innate immune cells (macrophages, neutrophils).
    • Adaptive Immunity: Aberrant T-cell responses, particularly an imbalance towards pro-inflammatory Th2 and Th17 cells, and overproduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12, IL-23).
  • Genetic Predisposition: Over 200 susceptibility loci identified, with genes involved in innate immunity, epithelial barrier function, and T-cell regulation (e.g., HLA, IL-10, GPR65, CARD9). However, no single gene mutation accounts for a large proportion of cases, unlike Crohn's disease (e.g., NOD2).
  • Environmental Triggers:
    • Gut Microbiota: Dysbiosis (imbalance in microbial composition and function) is consistently observed, with decreased diversity and alterations in specific bacterial species. This can impair barrier function and modulate immune responses.
    • Diet: High intake of red meat, refined sugars, and low fiber may contribute, though evidence is less robust than for Crohn's disease.
    • NSAIDs: Can exacerbate flares, possibly by impairing gut barrier function and altering the microbiome.
    • Infections: Prior enteric infections (e.g., C. difficile, Salmonella, Campylobacter) may trigger or exacerbate UC in susceptible individuals.
    • Smoking: Unlike Crohn's disease, current smoking is protective against UC onset and often worsens disease course upon cessation. Former smokers have a higher risk of developing UC.
• Risk Factors:
  • Genetics/Family History: First-degree relatives of UC patients have a 4-20 times higher risk.
  • Ethnicity: Ashkenazi Jewish descent.
  • Geography: Developed countries, urban areas.
  • Dietary Factors: Potentially a Westernized diet (high fat, sugar, processed foods; low fiber).
  • NSAIDs: Can trigger or worsen flares.
  • Infections: Prior enteric infections.
  • Appendectomy (before age 20): Paradoxically, appendectomy is a protective factor for UC, particularly if performed for appendicitis, suggesting a role for the appendix in gut immunity.
  • Ex-smokers: Higher risk compared to never-smokers and current smokers.
• Protective Factors:
  • Current Smoking: Paradoxically associated with a reduced risk of UC, though highly detrimental to overall health. Disease often flares upon smoking cessation.
  • Appendectomy: Particularly if performed in childhood/adolescence.
  • Breastfeeding: May reduce risk in offspring.
  • Oral Contraceptives: Some conflicting evidence, but generally not a strong protective factor.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Vary depending on disease extent and severity.
  • Bloody Diarrhea: Most common and characteristic symptom (80-90%). Stool often contains mucus and pus. Frequency correlates with severity.
  • Tenesmus: Persistent, painful, ineffective straining to defecate, especially with proctitis or left-sided colitis.
  • Urgency: Immediate need to defecate.
  • Abdominal Pain: Often crampy, lower abdominal pain, relieved by defecation. Less common or severe than in Crohn's.
  • Weight Loss: Common in moderate to severe disease due to malabsorption, decreased appetite, and inflammation.
  • Fatigue: Common, related to chronic inflammation, anemia, and nutritional deficiencies.
  • Extraintestinal Manifestations (EIMs): Occur in 25-40% of patients, often correlate with disease activity, but some can occur independently.
    • Arthralgias/Arthritis: Peripheral (migratory, oligoarticular, affecting large joints) or axial (sacroiliitis, ankylosing spondylitis).
    • Skin Lesions: Erythema nodosum (tender, red nodules, usually on shins), pyoderma gangrenosum (painful, necrotic ulcers with violaceous borders).
    • Ocular Manifestations: Uveitis (most common), episcleritis, conjunctivitis.
    • Hepatobiliary: Primary sclerosing cholangitis (PSC) – often progressive and independent of UC activity, increases risk of cholangiocarcinoma.
    • Renal: Nephrolithiasis (due to chronic dehydration, altered calcium/oxalate metabolism).
    • Thromboembolic Events: Increased risk of deep vein thrombosis and pulmonary embolism, especially during active flares.
• Early Signs:
  • Mild, intermittent rectal bleeding.
  • Increased stool frequency (e.g., 2-3 loose stools per day).
  • Mild tenesmus or urgency.
• Advanced Signs:
  • Frequent, bloody bowel movements (e.g., >6-10 per day).
  • Severe abdominal pain, often diffuse.
  • Fever (>37.8°C), tachycardia, orthostatic hypotension.
  • Signs of systemic toxicity: severe dehydration, electrolyte imbalance.
  • Significant weight loss, anemia.
  • Signs of toxic megacolon (abdominal distention, tenderness, rebound, decreased bowel sounds).
• Atypical Presentations:
  • Fulminant colitis without prior history.
  • Isolated EIMs preceding gastrointestinal symptoms.
  • Initial presentation mimicking irritable bowel syndrome (IBS) or infectious colitis.
  • Steroid-dependent or refractory disease requiring early advanced therapies.

Physical Examination

• Inspection:
  • General: Pallor (anemia), signs of dehydration (dry mucous membranes, reduced skin turgor).
  • Abdomen: Distention (toxic megacolon, severe colitis), scars from previous surgery.
  • Perianal: Usually normal in UC (unlike Crohn's where fistulas, fissures are common).
  • Skin: Erythema nodosum, pyoderma gangrenosum.
  • Joints: Swelling, redness, warmth, tenderness (arthritis).
  • Eyes: Redness, photophobia (uveitis, episcleritis).
• Palpation:
  • Abdomen: Mild to moderate diffuse or left-sided tenderness. In severe cases, rebound tenderness and guarding indicate peritonitis or toxic megacolon.
  • Rectum (DRE): Blood and mucus on glove, anal tone, tenderness. Usually no perianal fistulas or abscesses.
• Special Tests:
  • Orthostatic Vital Signs: To assess for dehydration and hypovolemia, particularly in severe flares.
  • Assessment for Toxic Megacolon: Marked abdominal distention, tenderness, tympany on percussion, reduced/absent bowel sounds.

Diagnostic Approach

The diagnosis of UC requires a combination of clinical symptoms, endoscopic findings, and histological confirmation, along with exclusion of other causes of colitis.

History Taking

• Key Questions:
  • Nature of symptoms: Bloody diarrhea (frequency, consistency, presence of mucus/pus), abdominal pain (location, character, severity), urgency, tenesmus, nocturnal awakenings for defecation.
  • Duration and pattern of symptoms: Acute onset vs. chronic relapsing-remitting course.
  • Constitutional symptoms: Fever, weight loss, fatigue, night sweats.
  • Extraintestinal symptoms: Joint pain/swelling, skin rashes, eye redness/pain, oral ulcers.
  • Family history: IBD, autoimmune diseases.
  • Medication history: Recent antibiotic use (r/o C. difficile), NSAID use, recent travel, use of immunomodulators/biologics for other conditions.
  • Smoking history: Current, former, never.
  • Impact on quality of life: Work, school, social activities.
• Red Flags: Warning signs requiring urgent attention, suggesting severe disease or complications.
  • High frequency of bloody stools (>6 per day)
  • Fever (>37.8°C)
  • Tachycardia (>90 bpm)
  • Severe abdominal tenderness or distention
  • Signs of dehydration or orthostasis
  • Significant unintentional weight loss (>10% body weight)
  • Signs of peritonitis (rebound, guarding)
  • Severe anemia requiring transfusion

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC):
    • Anemia: Common (iron deficiency from chronic blood loss, anemia of chronic disease).
    • Leukocytosis: Can indicate inflammation or infection (e.g., C. difficile).
    • Thrombocytosis: Acute phase reactant, correlates with inflammation.
  • Inflammatory Markers:
    • Erythrocyte Sedimentation Rate (ESR): Elevated in active inflammation.
    • C-reactive Protein (CRP): More sensitive and rapid indicator of acute inflammation. Values often correlate with disease activity (though can be normal in isolated proctitis).
  • Renal and Liver Function Tests (LFTs): Assess for dehydration, electrolyte imbalances, and EIMs (e.g., primary sclerosing cholangitis, drug-induced liver injury).
  • Albumin: Hypoalbuminemia indicates severe inflammation, malnutrition, or protein-losing enteropathy.
  • Stool Studies:
    • Stool Culture: To rule out bacterial enteropathogens (e.g., Salmonella, Shigella, Campylobacter, E. coli O157:H7).
    • Clostridioides difficile toxin (PCR or EIA): Essential to rule out C. difficile infection, which can mimic or complicate UC flares.
    • Ova and Parasites: To rule out parasitic infections (e.g., Entamoeba histolytica).
    • Fecal Calprotectin (FCP) or Fecal Lactoferrin: Highly sensitive non-invasive markers of intestinal inflammation. Elevated levels suggest active inflammation and help differentiate IBD from IBS. FCP >250 mcg/g strongly suggests IBD. Used for diagnosis, monitoring, and predicting relapse.
• Confirmatory:
  • Colonoscopy with Ileoscopy and Biopsies: The gold standard for diagnosis.
    • Visual Findings: Continuous inflammation extending proximally from the rectum, loss of vascular pattern, erythema, granularity, friability, ulcerations, pseudopolyps in chronic disease. The inflammation is typically circumferential.
    • Biopsies: Multiple biopsies from different segments (including rectum, sigmoid, descending, transverse, ascending colon, and terminal ileum) are crucial for histological confirmation and to assess disease extent and severity.
    • Histology: Crypt architectural distortion, crypt abscesses, basal plasmacytosis, mucin depletion, and inflammatory cell infiltrates (neutrophils, lymphocytes, plasma cells) in the lamina propria. Granulomas are typically absent (present in Crohn's).
    • Differential Diagnosis: Ileal biopsy helps exclude Crohn's disease (which often has skip lesions or ileal involvement).
• Monitoring:
  • CBC, ESR, CRP, Albumin: Periodically to assess disease activity and nutritional status.
  • Fecal Calprotectin: Non-invasive marker for monitoring mucosal healing and predicting relapse. Levels typically <100 mcg/g indicate remission.
  • Therapeutic Drug Monitoring (TDM): For biologics (e.g., infliximab, adalimumab) to assess drug levels and antibody formation, guiding dose adjustments.
  • Colorectal Cancer Surveillance: Regular surveillance colonoscopies with biopsies are recommended due to increased risk of dysplasia/cancer in long-standing, extensive UC.

Imaging

• Recommended:
  • Abdominal Plain Radiograph (X-ray): Primarily used in acute severe colitis to assess for toxic megacolon (colonic dilation >6 cm, especially transverse colon), perforation (free air under diaphragm), or severe constipation/obstruction.
• Advanced:
  • CT Enterography (CTE) / MR Enterography (MRE): Not routinely used for initial diagnosis of UC, but helpful in:
    • Differentiating UC from Crohn's disease: Especially when there is diagnostic uncertainty, as they can identify small bowel involvement or transmural inflammation characteristic of Crohn's.
    • Assessing complications: Fistulas, abscesses, strictures (though less common in UC than Crohn's).
    • Assessing extent of inflammation: Particularly when colonoscopy is incomplete or contraindicated due to severe disease.
  • CT Abdomen/Pelvis: Useful for assessing acute complications like perforation, abscesses, or toxic megacolon if plain X-ray is equivocal.
  • Barium Enema (Double Contrast): Historically used, but largely replaced by colonoscopy due to inferior mucosal detail and lack of biopsy capability. May still be used in rare cases where colonoscopy is not feasible.

Management

Management of UC aims to induce and maintain remission, improve quality of life, prevent complications, and avoid surgery. Treatment selection depends on disease extent, severity, patient factors, and response to previous therapies.

Acute Management

Assessing Severity of Flare (Truelove and Witts criteria for severe UC):

• Mild: <4 bloody stools/day, no systemic signs of toxicity.
• Moderate: 4-6 bloody stools/day, minimal systemic toxicity.
• Severe: ≥6 bloody stools/day PLUS at least one of: temperature ≥37.8°C, pulse ≥90 bpm, Hb <10.5 g/dL, ESR >30 mm/h or CRP >30 mg/L.

• Fulminant: ≥10 bloody stools/day PLUS signs of severe systemic toxicity (hypotension, colonic dilation ≥6 cm, mental status changes, need for transfusion). High risk of toxic megacolon.

• Immediate:

  • Hospitalization: For severe or fulminant flares.
  • NPO/Bowel Rest: In severe cases, to reduce colonic stimulation.
  • Hydration and Electrolyte Correction: IV fluids to correct dehydration and electrolyte imbalances (e.g., hypokalemia from diarrhea).
  • Rule out infection: Send stool for C. difficile toxin, culture, O&P. Treat any identified infection.
  • Broad-spectrum antibiotics: Consider for suspected sepsis or toxic megacolon while awaiting cultures, or if perforation is suspected.
• Stabilization:
  • Systemic Corticosteroids: Cornerstone for inducing remission in moderate to severe flares.
    • Oral Prednisone: 40-60 mg/day (or equivalent) for moderate flares, often tapered over 6-8 weeks.
    • Intravenous Corticosteroids: For severe or fulminant flares.
      • Methylprednisolone: 40-60 mg IV every 8-12 hours.
      • Hydrocortisone: 100 mg IV every 6-8 hours.
    • Duration: Typically 3-5 days of IV steroids for initial response, then transition to oral steroids for tapering.
  • Rectal Mesalamine/Steroids: For proctitis or left-sided disease that is moderate. Can be used as adjuncts in more extensive disease.
    • Mesalamine suppositories/enemas: 1g daily.
    • Budesonide foam/enema: 2mg daily.
• Emergency:
  • Toxic Megacolon: A life-threatening complication characterized by acute colonic dilation, systemic toxicity, and transmural inflammation.
    • Management: NPO, NG tube for decompression, IV fluids and electrolytes, broad-spectrum IV antibiotics (e.g., metronidazole + ciprofloxacin/piperacillin-tazobactam), IV corticosteroids. Frequent abdominal X-rays (every 12-24 hours) to monitor colonic diameter.
    • Surgical Consultation: Early surgical consultation (total colectomy) is crucial if no clinical improvement within 24-72 hours of medical therapy, or if signs of perforation, ischemia, or intractable hemorrhage develop.
  • Severe Hemorrhage: Rare but possible. May require blood transfusions. Surgery if medical management fails.
  • Perforation: Surgical emergency (total colectomy).

Chronic Management

Goals are to maintain steroid-free remission, achieve mucosal healing, improve quality of life, and prevent complications.

• Pharmacological:

  • 5-Aminosalicylates (5-ASAs):
    • Mechanism: Topical anti-inflammatory effect, thought to modulate inflammatory mediators (e.g., leukotrienes, prostaglandins) and scavenge free radicals.
    • Indications: First-line for induction and maintenance of remission in mild to moderate UC, especially proctitis and left-sided disease. Less effective for severe or extensive disease.
    • Examples:
      • Mesalamine (Mesalazine): Oral forms (e.g., Asacol HD, Lialda, Apriso, Pentasa) and rectal forms (suppositories, enemas).
        • Oral Dosing: 2.4-4.8 g/day in divided doses or once daily. Higher doses generally more effective for induction.
        • Rectal Dosing: Suppositories (1g/day) for proctitis; Enemas (1-4g/day) for proctosigmoiditis/left-sided colitis. Often used in combination with oral 5-ASAs for left-sided disease.
      • Sulfasalazine: Prodrug (sulfapyridine + 5-ASA). Less commonly used due to higher side effect profile (headache, nausea, rash, oligospermia, bone marrow suppression, folate deficiency) from the sulfa moiety.
        • Dosing: 2-4 g/day.
  • Corticosteroids:
    • Mechanism: Potent anti-inflammatory and immunosuppressive effects.
    • Indications: Induction of remission in moderate to severe flares. NOT for long-term maintenance due to significant systemic side effects.
    • Examples:
      • Prednisone: 40-60 mg/day oral, tapered over 6-8 weeks.
      • Methylprednisolone/Hydrocortisone: IV for severe flares (as above).
      • Budesonide MMX (Uceris): Oral controlled-release formulation that delivers budesonide to the colon, reducing systemic absorption and side effects.
        • Dosing: 9 mg/day oral for induction of mild to moderate active UC for up to 8 weeks. NOT for maintenance.
  • Immunomodulators:
    • Mechanism: Suppress the immune system by interfering with lymphocyte proliferation and function. Slow onset of action (weeks to months).
    • Indications: Steroid-dependent or steroid-refractory UC, or to maintain remission in patients who have achieved remission with biologics.
    • Examples:
      • Thiopurines: Azathioprine (AZA) and 6-mercaptopurine (6-MP).
        • Dosing: AZA: 2.0-2.5 mg/kg/day; 6-MP: 1.0-1.5 mg/kg/day.
        • Monitoring: Requires regular monitoring of CBC (leukopenia, anemia, thrombocytopenia) and LFTs (hepatotoxicity). Genotyping for Thiopurine S-methyltransferase (TPMT) activity is recommended before initiation to identify patients at risk of severe myelosuppression.
      • Methotrexate (MTX): Less commonly used for UC than Crohn's, but an option for thiopurine intolerance/failure.
        • Dosing: 15-25 mg/week (oral or subcutaneous).
        • Monitoring: CBC, LFTs, renal function. Folate supplementation is crucial.
  • Biologic Therapies:
    • Mechanism: Target specific pro-inflammatory cytokines or cell adhesion molecules, highly effective for moderate to severe UC.
    • Indications: For patients who fail 5-ASA therapy, are steroid-dependent/refractory, or have severe/extensive disease. Often used after immunomodulators or concurrently.
    • Examples:
      • Anti-TNF agents: Infliximab (Remicade), Adalimumab (Humira), Golimumab (Simponi).
        • Infliximab: IV infusion. Induction: 5 mg/kg at weeks 0, 2, 6. Maintenance: 5 mg/kg every 8 weeks. Dose escalation (up to 10 mg/kg every 4 weeks) often needed.
        • Adalimumab: Subcutaneous injection. Induction: 160 mg at week 0, 80 mg at week 2. Maintenance: 40 mg every other week. Dose escalation (40 mg weekly) often needed.
        • Golimumab: Subcutaneous injection. Induction: 200 mg at week 0, 100 mg at week 2. Maintenance: 50 mg or 100 mg every 4 weeks.
        • Side Effects: Infusion reactions, infections (TB, fungal, opportunistic), lymphoma, demyelinating disease, heart failure exacerbation. Screening for TB and HBV is mandatory before initiation.
      • Anti-integrin agents: Vedolizumab (Entyvio).
        • Mechanism: Selectively blocks lymphocyte trafficking to the gut, leading to a gut-specific anti-inflammatory effect. Generally safer regarding systemic infections compared to anti-TNFs.
        • Dosing: IV infusion. Induction: 300 mg at weeks 0, 2, 6. Maintenance: 300 mg every 8 weeks.
        • Side Effects: Nasopharyngitis, headache, arthralgia, fatigue. Low risk of PML.
      • Anti-IL-12/23 agents: Ustekinumab (Stelara).
        • Mechanism: Targets the p40 subunit common to IL-12 and IL-23, key cytokines in inflammation.
        • Dosing: IV induction (weight-based, one-time dose). Maintenance: 90 mg subcutaneous every 8 weeks.
        • Side Effects: Similar to anti-TNFs, but often better tolerated. Infections, headache, fatigue, nasopharyngitis.
  • Janus Kinase (JAK) Inhibitors:
    • Mechanism: Small molecule inhibitors that block intracellular signaling pathways involving JAK enzymes, crucial for cytokine-mediated inflammation.
    • Examples: Tofacitinib (Xeljanz). Oral administration.
    • Indications: Moderate to severe active UC in adults who have failed or are intolerant to anti-TNF therapy.
    • Dosing: Induction: 10 mg oral twice daily for 8 weeks. Maintenance: 5 mg oral twice daily. For patients who lose response, can increase to 10 mg twice daily.
    • Side Effects: Infections (herpes zoster, opportunistic), VTE (DVT/PE), dyslipidemia, elevated LFTs, anemia, neutropenia. Black box warning for serious infections, malignancy, MACE, and VTE. Careful monitoring required.
  • Sphingosine-1-Phosphate (S1P) Receptor Modulators:
    • Mechanism: Blocks lymphocyte egress from lymph nodes, reducing circulating lymphocytes available to enter the gut.
    • Examples: Ozanimod (Zeposia). Oral administration.
    • Indications: Moderate to severe active UC in adults.
    • Dosing: Gradual dose escalation over 7 days to a target dose of 0.92 mg once daily.
    • Side Effects: Bradycardia (requires initial observation), infections, elevated LFTs, macular edema, hypertension. Baseline ECG, LFTs, ophthalmologic exam, and varicella zoster virus (VZV) serology required.

• Non-pharmacological:

  • Diet: No specific "UC diet," but general recommendations include:
    • Balanced Diet: Adequate calories, protein, vitamins, and minerals.
    • Trigger Foods: Identify and avoid foods that exacerbate symptoms (e.g., high fiber during flares, lactose if intolerant, spicy foods). Keep a food diary.
    • Low Residue Diet: May be beneficial during flares to reduce bowel movements and discomfort.
    • Nutritional Supplements: Vitamin D, calcium, iron, B12, folate may be needed due to malabsorption or medication side effects.
  • Smoking Cessation: Crucial, especially for ex-smokers as disease often flares upon cessation. While current smoking is paradoxically protective against UC, the overall health risks outweigh any perceived benefit.
  • Stress Management: Stress does not cause UC but can exacerbate symptoms. Techniques include mindfulness, meditation, yoga, psychotherapy.
  • Probiotics: Evidence is mixed; some strains (e.g., VSL#3) may have modest benefit in pouchitis or maintaining remission in mild UC, but not routinely recommended for active disease.
  • Psychosocial Support: Support groups, counseling to cope with chronic illness.

• Monitoring:

  • Clinical Assessment: Regular symptom review (stool frequency, bleeding, pain, urgency, EIMs, QoL).
  • Laboratory Monitoring: ESR, CRP, CBC, albumin periodically (e.g., every 3-6 months in remission, more frequently in active disease). Fecal calprotectin.
  • Therapeutic Drug Monitoring (TDM): For biologics, especially anti-TNFs, to optimize dosing and manage loss of response.
  • Endoscopic Monitoring:
    • Mucosal Healing: Endoscopic evaluation (colonoscopy) is the preferred method to confirm remission and mucosal healing (absence of active inflammation on endoscopy).
    • Colorectal Cancer Surveillance:
      • Timing: Beginning 8-10 years after diagnosis of pancolitis, or 15-20 years for left-sided colitis. Not typically needed for isolated proctitis unless it extends.
      • Frequency: Every 1-3 years depending on risk factors (disease extent, duration, severity of inflammation, family history of CRC, presence of PSC).
      • Technique: High-definition chromoendoscopy with targeted biopsies is preferred over random biopsies for dysplasia detection.

Treatment Algorithms

Approach is generally step-up or top-down, tailored to disease severity and extent.

• First-Line:
  • Ulcerative Proctitis (E1):
    • Induction & Maintenance: Topical 5-ASAs (mesalamine suppositories 1g daily) are first-line. Oral 5-ASAs can be added if needed (e.g., 2.4-4.8g/day). Topical steroids (budesonide foam/enema) are an alternative.
  • Left-Sided Colitis (E2):
    • Induction: Oral 5-ASAs (2.4-4.8g/day) plus topical 5-ASAs (mesalamine enemas 1-4g/day) or topical steroids. For moderate flares, consider oral corticosteroids (e.g., prednisone 40-60mg/day taper).
    • Maintenance: Oral 5-ASAs (2.4-4.8g/day), often combined with topical 5-ASAs for persistent symptoms.
  • Extensive Colitis (E3) - Mild-Moderate:
    • Induction: Oral 5-ASAs (4.8g/day). If poor response or moderate activity, add oral corticosteroids (e.g., prednisone 40-60mg/day taper). Oral budesonide MMX 9mg/day for up to 8 weeks.
    • Maintenance: Oral 5-ASAs (2.4-4.8g/day).
• Second-Line (for moderate-severe disease, or failure of first-line agents/steroid-dependent):
  • Immunomodulators: Thiopurines (AZA/6-MP) for steroid-dependent UC or as maintenance for biologic-induced remission. Onset of action is slow (2-3 months).
  • Biologics: Anti-TNF (infliximab, adalimumab, golimumab), anti-integrin (vedolizumab), or anti-IL-12/23 (ustekinumab). Choice depends on patient profile, comorbidities, and physician experience. Usually initiated for patients with moderate-to-severe disease who have failed 5-ASAs and/or corticosteroids.
  • JAK Inhibitors: Tofacitinib, for moderate to severe UC in adults who have failed anti-TNF therapy or have contraindications.
• Refractory Cases: Management of treatment failures
  • Optimization of Current Therapy:
    • Biologic Optimization: Dose escalation, reduction of dosing interval, or switching to another biologic within the same class (e.g., infliximab to adalimumab).
    • Combination Therapy: Adding an immunomodulator (e.g., AZA/6-MP) to a biologic (e.g., anti-TNF) to improve efficacy and reduce immunogenicity (e.g., reduce anti-drug antibody formation).
    • Therapeutic Drug Monitoring (TDM): To guide dose adjustments, especially for biologics. If drug levels are low, dose escalation; if high with no response, consider switching to a different mechanism of action.
  • Switching Mechanisms of Action: If failure of one biologic class (e.g., anti-TNF), switch to a different class (e.g., anti-integrin, anti-IL-12/23, JAK inhibitor).
  • Clinical Trials: Enrollment in clinical trials for novel agents.
  • Surgery (Colectomy): The definitive treatment for medically refractory UC.
    • Indications: Medically refractory disease (failure of all reasonable medical therapies to induce or maintain remission), high-grade dysplasia or colorectal cancer, toxic megacolon unresponsive to medical therapy, perforation, intractable hemorrhage.
    • Procedure: Total proctocolectomy with ileal pouch-anal anastomosis (IPAA, "J-pouch") is the reconstructive procedure of choice, preserving continence. A temporary diverting ileostomy is often created and reversed in a second stage.
    • Alternative: Permanent ileostomy (end ileostomy) may be performed if IPAA is contraindicated or patient preference.

Complications

• Common:
  • Anemia: Due to chronic blood loss and/or anemia of chronic disease.
  • Dehydration and Electrolyte Imbalances: From chronic diarrhea.
  • Malnutrition and Weight Loss: Due to decreased appetite, inflammation, and nutrient malabsorption (less common in UC than Crohn's).
  • Perianal Disease: Less common than in Crohn's, but can include hemorrhoids, fissures, and rarely abscesses.
  • Extraintestinal Manifestations (EIMs): Arthritis, skin lesions (erythema nodosum, pyoderma gangrenosum), ocular inflammation (uveitis, episcleritis), primary sclerosing cholangitis (PSC).
• Serious:
  • Toxic Megacolon: Rapidly progressive, life-threatening colonic dilation (>6 cm) with systemic toxicity. Risk of perforation.
  • Colonic Perforation: A surgical emergency, typically a consequence of severe inflammation or toxic megacolon.
  • Severe Hemorrhage: Rare, but can be life-threatening.
  • Venous Thromboembolism (VTE): Increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), especially during flares and hospitalizations. Prophylaxis often indicated during hospitalization.
• Long-term:
  • Colorectal Cancer (CRC): Increased risk compared to general population, especially with extensive disease, long duration (>8-10 years), early disease onset, severe inflammation, and primary sclerosing cholangitis (PSC). Requires regular surveillance colonoscopies.
  • Primary Sclerosing Cholangitis (PSC): Chronic cholestatic liver disease, strongly associated with UC (4-5% of UC patients). Increases CRC risk in UC.
  • Osteoporosis/Osteopenia: Due to chronic inflammation, malabsorption, and long-term corticosteroid use.
  • Drug-Related Side Effects: From long-term immunosuppressants (e.g., infections, malignancy risk with thiopurines/biologics, nephrotoxicity with cyclosporine).
  • Pouchitis: Inflammation of the ileal pouch after IPAA surgery. Occurs in up to 50% of patients within 10 years, can be chronic.

Prognosis

• Factors Affecting Outcome:
  • Disease Extent: Extensive colitis (pancolitis) has a worse prognosis and higher risk of complications (e.g., CRC, toxic megacolon) than proctitis or left-sided colitis.
  • Disease Severity: Severe flares are associated with higher morbidity and mortality. Need for hospitalization or IV steroids predicts a more complicated course.
  • Early Onset: Diagnosis at a young age is associated with more extensive disease and higher lifetime risk of complications.
  • Extraintestinal Manifestations: Presence of certain EIMs, especially PSC, indicates a more severe disease course and worse prognosis.
  • Initial Response to Therapy: Failure to achieve steroid-free remission or development of steroid-dependence/refractory disease predicts a poorer long-term outcome and higher likelihood of surgery.
  • Mucosal Healing: Achievement of mucosal healing on endoscopy is a strong predictor of sustained clinical remission and reduced risk of complications (including surgery and CRC).
• Survival: Overall mortality in UC is slightly higher than the general population, primarily due to complications like CRC, severe flares, or surgical complications. However, with effective medical and surgical management, most patients have a near-normal life expectancy.
• Quality of Life: Can be significantly impacted by chronic symptoms, frequent flares, medication side effects, and the need for frequent medical visits or surgery. The goal of modern therapy is to achieve sustained symptom control and mucosal healing to restore a good quality of life. Patients often experience fatigue, anxiety, and depression.

Prevention

• Primary: Currently, there is no definitive primary prevention strategy for UC. Research is ongoing into the role of diet, microbiome modulation, and early life exposures.
  • Diet: While no specific diet prevents UC, a balanced diet rich in fruits, vegetables, and fiber may promote gut health.
  • Smoking Cessation: Although smoking is paradoxically protective for UC, smoking cessation is strongly recommended for overall health. Ex-smokers have a higher risk of developing UC compared to never-smokers or current smokers.
  • Appendectomy: Early appendectomy for appendicitis is associated with a reduced risk of UC development, but it's not a preventive measure for UC.
• Secondary: Focuses on early detection and intervention to prevent disease progression and complications.
  • Prompt Diagnosis: Early recognition of symptoms and timely diagnosis (colonoscopy with biopsies) allows for earlier initiation of appropriate therapy.
  • Optimal Medical Management: Adherence to prescribed medications, aiming for mucosal healing rather than just symptomatic remission, can prevent disease progression and reduce the need for surgery.
  • Monitoring of Inflammatory Markers: Regular assessment of Fecal Calprotectin, CRP, ESR can identify subclinical inflammation and predict impending flares, allowing for proactive adjustments to therapy.
• Tertiary: Focuses on preventing complications and optimizing outcomes in established UC.
  • Colorectal Cancer Surveillance: Regular surveillance colonoscopies for patients with long-standing, extensive UC to detect and remove dysplasia before it progresses to cancer.
  • Bone Density Monitoring: Regular screening (DEXA scans) and management of osteoporosis/osteopenia, especially in patients with long-term steroid use.
  • Vaccinations: Ensure patients are up-to-date with routine vaccinations (influenza, pneumococcal, tetanus-diphtheria-pertussis). Patients on immunosuppressants require specific considerations:
    • Live Vaccines: Contraindicated (MMR, varicella, yellow fever, oral polio, live attenuated influenza) for patients on moderate to high dose steroids, immunomodulators, or biologics.
    • Inactivated Vaccines: Recommended (influenza, pneumococcal, HPV, tetanus, HBV, inactivated polio, Tdap, Shingrix).
  • Smoking Cessation: For established UC, quitting smoking is strongly encouraged, though it may paradoxically precipitate a flare. Managed closely by the gastroenterologist.

Special Populations

• Pediatric:
  • Presentation: Often more extensive disease (pancolitis) and more severe at presentation than adults. More prominent growth failure, delayed puberty, and nutritional deficiencies. EIMs can be more common.
  • Diagnosis: Similar to adults, but emphasis on ruling out other causes of colitis.
  • Management: Goal is to achieve and maintain remission, ensure normal growth and development, and prevent complications.
    • Corticosteroids: Used for induction but careful with long-term use due to impact on growth.
    • 5-ASAs: First-line for mild-moderate disease.
    • Immunomodulators/Biologics: Often used earlier in the disease course compared to adults due to the severity and impact on growth. Infliximab and adalimumab are approved for pediatric UC.
    • Nutritional Support: Crucial for growth and development.
    • Psychosocial Support: For patient and family, dealing with chronic illness.
• Geriatric:
  • Presentation: Often atypical, less severe symptoms, or may present with complications. Higher rates of left-sided colitis. Diagnosis may be delayed.
  • Comorbidities: Higher prevalence of comorbidities (cardiovascular disease, diabetes, renal/hepatic impairment) and polypharmacy, which complicates treatment selection.
  • Medication Considerations: Increased risk of drug side effects (e.g., infections with immunosuppressants, bone density issues with steroids, renal impairment with 5-ASAs). Drug-drug interactions are common. Careful monitoring of kidney function with 5-ASAs is essential.
  • Surgery: Higher rates of postoperative complications.
• Pregnancy:
  • Pre-conception Counseling: Optimize disease control BEFORE conception. Active disease at conception increases risk of adverse pregnancy outcomes (preterm birth, low birth weight, miscarriage).
  • Medication Safety: Most UC medications are considered safe during pregnancy and lactation.
    • 5-ASAs: Generally safe.
    • Corticosteroids: Safe for short-term use for flares. Budesonide is preferred due to low systemic absorption.
    • Thiopurines (AZA/6-MP): Generally safe, but discuss risks/benefits.
    • Biologics: Infliximab, adalimumab, certolizumab, vedolizumab are generally considered safe. Certolizumab is preferred by some in third trimester due to minimal placental transfer. Ustekinumab data is growing and generally favorable. Tofacitinib and Ozanimod are not recommended in pregnancy.
    • Folate Supplementation: Crucial for all pregnant patients, especially those on methotrexate (though MTX is contraindicated in pregnancy) or sulfasalazine.
  • Delivery: Vaginal delivery is usually preferred unless contraindicated by active perianal disease (in Crohn's) or obstetric reasons. IPAA does not preclude vaginal delivery.
  • Flare Management: Manage flares aggressively during pregnancy to prevent adverse outcomes.
• Comorbidities:
  • Autoimmune Diseases: UC patients have an increased risk of other autoimmune conditions (e.g., psoriasis, thyroid disease, rheumatoid arthritis). Management should consider shared immune pathways and potential drug interactions or contraindications (e.g., anti-TNF for rheumatoid arthritis).
  • Cardiovascular Disease: Increased risk of VTE. Careful monitoring with JAK inhibitors due to MACE risk.
  • Infections: Patients on immunosuppressants are at higher risk of various infections. Screening for TB, HBV, VZV before biologics/JAK inhibitors is critical. Vaccinations are crucial.
  • Malignancy: Increased risk of colorectal cancer. Immunosuppressants (especially thiopurines, anti-TNF) may carry a small increased risk of non-melanoma skin cancer and lymphoma. Regular skin checks are important.

Clinical Pearls

• Diagnostic:
  • Always rule out infection: Before initiating immunosuppressants for an UC flare, ensure C. difficile and other enteric pathogens are excluded. Treating infection can avoid unnecessary immunosuppression.
  • Fecal Calprotectin is your friend: A powerful non-invasive tool to differentiate IBD from IBS, monitor disease activity, and predict relapse. Levels correlate well with mucosal inflammation.
  • Don't rely solely on symptoms: Clinical remission does not always equate to mucosal healing. Endoscopy with biopsies is essential to confirm mucosal healing, which is a key treatment target.
  • Consider EIMs: Extraintestinal manifestations can be the presenting symptom or occur independently of gut activity. A thorough systems review is critical.
• Treatment:
  • Mucosal Healing is the Goal: Aim for endoscopic remission, not just symptomatic remission, as it correlates with long-term steroid-free remission, reduced flares, and lower risk of complications including CRC.
  • Step-up vs. Top-down: For severe disease, a "top-down" approach (early use of biologics/JAK inhibitors) may be more effective than a traditional "step-up" approach, reducing steroid exposure and preventing complications.
  • Steroids are for induction, not maintenance: Emphasize to patients the importance of tapering steroids and transitioning to maintenance therapy to avoid long-term side effects.
  • Therapeutic Drug Monitoring (TDM): Especially for anti-TNF biologics, TDM can optimize dosing, manage loss of response, and improve outcomes.
  • Surgery is a treatment, not a failure: For medically refractory disease or complications, surgery (colectomy with IPAA) can be life-changing and life-saving, restoring quality of life.
• Pitfalls:
  • Under-treating the disease: Not escalating therapy appropriately for moderate-severe disease, leading to chronic symptoms, steroid dependence, and complications.
  • Ignoring C. difficile: Failing to test for and treat C. difficile in every flare, which can worsen inflammation and lead to poor response to IBD therapies.
  • Over-reliance on steroids: Prolonged steroid use without adequate maintenance therapy leads to significant side effects.
  • Poor adherence to maintenance therapy: Patients often stop medication when feeling well, leading to relapse. Emphasize the importance of continuous therapy.
  • Missing CRC: Inadequate surveillance for colorectal cancer in long-standing UC patients.

Recent Updates

• Guidelines:
  • AGA (American Gastroenterological Association), ACG (American College of Gastroenterology), ECCO (European Crohn's and Colitis Organisation): Recent updates generally emphasize "Treat-to-Target" strategies, with mucosal healing as a primary therapeutic goal, guided by endoscopic and biomarker assessment (e.g., Fecal Calprotectin).
  • Early Biologic Use: Increasing evidence supports earlier initiation of biologics or JAK inhibitors in moderate-to-severe UC to achieve deeper remission and improve long-term outcomes, moving away from a strict step-up approach.
• Evidence:
  • New Therapies: Emergence of novel mechanisms of action beyond anti-TNF, including JAK inhibitors (e.g., Tofacitinib, Upadacitinib) and S1P receptor modulators (e.g., Ozanimod, Etrasimod), offering oral options and alternative targets for refractory disease.
  • Real-world Effectiveness: Growing data from real-world registries and comparative effectiveness studies are helping guide optimal sequencing and choice of biologics and small molecules.
  • Role of Microbiome: Ongoing research into the gut microbiome's role in UC pathogenesis and potential therapeutic interventions (e.g., Fecal Microbiota Transplantation - FMT) for select refractory cases (though not standard of care for UC).
• Controversies:
  • When to De-escalate Therapy: Limited data on safely de-escalating or stopping biologics/immunomodulators in patients with deep and sustained remission. Often considered on a case-by-case basis due to high risk of relapse.
  • Optimal Treat-to-Target Strategy: While mucosal healing is accepted, the precise Fecal Calprotectin or endoscopic score thresholds for optimal target are still being refined.
  • Surgery vs. Medical Therapy: Debates continue regarding the optimal timing of surgery for medically refractory UC, especially with the increasing number of effective medical therapies available. Early surgical referral is still crucial for appropriate cases.

Key References

• Guidelines:
  • AGA Clinical Practice Guidelines on Ulcerative Colitis: American Gastroenterological Association. (Regularly updated).
  • ECCO Guidelines on Ulcerative Colitis: European Crohn's and Colitis Organisation. (Regularly updated, highly comprehensive).
  • ACG Clinical Guidelines: Ulcerative Colitis in Adults: American College of Gastroenterology. (Regularly updated).
• Studies:
  • ACT 1 & 2 (Infliximab): Landmark trials establishing infliximab efficacy in UC.
  • PURSUIT (Golimumab): Phase 3 trials for golimumab in UC.
  • GEMINI 1 (Vedolizumab): Phase 3 trial for vedolizumab in UC.
  • UNIFI (Ustekinumab): Phase 3 trial for ustekinumab in UC.
  • OCTAVE Induction & Maintenance (Tofacitinib): Phase 3 trials for tofacitinib in UC.
  • TRUE NORTH (Ozanimod): Phase 3 trials for Ozanimod in UC.
• Reviews:
  • UpToDate and DynaMed: Excellent comprehensive, evidence-based clinical reviews.
  • Gastroenterology, Gut, Clinical Gastroenterology and Hepatology (journals): Leading journals for primary research and review articles on IBD.